Literature DB >> 32354948

The Impact of Intraoperative Blood Loss on the Survival of Patients With Stage II/III Pancreatic Cancer.

Hiroshi Tamagawa1,2, Toru Aoyama3, Naoto Yamamoto4, Mariko Kamiya4, Masaaki Murakawa4, Yosuke Atsumi2, Masakatsu Numata2, Keisuke Kazama2, Kentaro Hara2, Norio Yukawa2, Yasushi Rino2, Munetaka Masuda2, Soichiro Morinaga4.   

Abstract

BACKGROUND: Pancreatic cancer is a fatal disease with a poor prognosis. Pancreatic cancer is often unresectable at the time of diagnosis, so the analysis of risk factors in patients with indications for surgery is important. We investigated the impact of intraoperative blood loss (IBL) on survival and recurrence in patients with stage II/III pancreatic cancer after curative surgery. PATIENTS AND METHODS: This study included 76 patients who underwent curative surgery for stage II/III pancreatic cancer between 2007 and 2012. The risk factors for overall (OS) and recurrence-free (RFS) survival were identified.
RESULTS: IBL of 1,000 ml was considered to be the optimal cut-off value for classification based on a receiver operating characteristic (ROC) curve analysis. The OS rates at 5 years after surgery in the groups with low and high IBL were 36.6% and 11.4%, respectively, which was a statistically significant difference (p=0.003). The RFS rates at 1 year after surgery were 49.8% and 24.6%, respectively, which was a significant difference (p=0.045). A multivariate analysis demonstrated that IBL was a significant independent risk factor for OS.
CONCLUSION: IBL is an independent prognostic factor after curative resection of stage II/III pancreatic cancer. The reduction of bleeding during surgery is necessary to improve the results of pancreatic cancer surgery. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Intraoperative blood loss; Pancreatic cancer; recurrence; survival

Mesh:

Year:  2020        PMID: 32354948      PMCID: PMC7279845          DOI: 10.21873/invivo.11931

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  23 in total

1.  Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients.

Authors:  K F D Kuhlmann; S M M de Castro; J G Wesseling; F J W ten Kate; G J A Offerhaus; O R C Busch; T M van Gulik; H Obertop; D J Gouma
Journal:  Eur J Cancer       Date:  2004-03       Impact factor: 9.162

2.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.

Authors:  Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

3.  Predicting survival after surgical resection for pancreatic ductal adenocarcinoma.

Authors:  Hyoun Jong Moon; Ji Yeong An; Jin Seok Heo; Seong Ho Choi; Jae Won Joh; Yong Il Kim
Journal:  Pancreas       Date:  2006-01       Impact factor: 3.327

Review 4.  Technical aspects of left-sided pancreatic resection for cancer.

Authors:  A Andrén-Sandberg; M Wagner; T Tihanyi; P Löfgren; H Friess
Journal:  Dig Surg       Date:  1999       Impact factor: 2.588

5.  Impact of operative blood loss on survival in invasive ductal adenocarcinoma of the pancreas.

Authors:  Shunji Nagai; Tsutomu Fujii; Yasuhiro Kodera; Mitsuro Kanda; Tevfik T Sahin; Akiyuki Kanzaki; Suguru Yamada; Hiroyuki Sugimoto; Shuji Nomoto; Shin Takeda; Satoshi Morita; Akimasa Nakao
Journal:  Pancreas       Date:  2011-01       Impact factor: 3.327

6.  Randomized prospective trial of pylorus-preserving vs. Classic duodenopancreatectomy (Whipple procedure): initial clinical results.

Authors:  C A Seiler; M Wagner; C Sadowski; C Kulli; M W Büchler
Journal:  J Gastrointest Surg       Date:  2000 Sep-Oct       Impact factor: 3.452

7.  Intraoperative blood loss is not a predictor of prognosis for pancreatic cancer.

Authors:  Kota Arima; Daisuke Hashimoto; Hirohisa Okabe; Risa Inoue; Takayoshi Kaida; Takaaki Higashi; Katsunobu Taki; Hidetoshi Nitta; Hiromitsu Hayashi; Akira Chikamoto; Toru Beppu; Hideo Baba
Journal:  Surg Today       Date:  2015-08-25       Impact factor: 2.549

8.  Intraoperative Blood Loss is Associated with Shortened Postoperative Survival of Patients with Stage II/III Gastric Cancer: Analysis of a Multi-institutional Dataset.

Authors:  Yuki Ito; Mitsuro Kanda; Seiji Ito; Yoshinari Mochizuki; Hitoshi Teramoto; Kiyoshi Ishigure; Toshifumi Murai; Takahiro Asada; Akiharu Ishiyama; Hidenobu Matsushita; Chie Tanaka; Daisuke Kobayashi; Michitaka Fujiwara; Kenta Murotani; Yasuhiro Kodera
Journal:  World J Surg       Date:  2019-03       Impact factor: 3.352

Review 9.  Pancreatic cancer.

Authors:  Terumi Kamisawa; Laura D Wood; Takao Itoi; Kyoichi Takaori
Journal:  Lancet       Date:  2016-01-30       Impact factor: 79.321

10.  Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma.

Authors:  Steven C Katz; Jinru Shia; Kui Hin Liau; Mithat Gonen; Leyo Ruo; William R Jarnagin; Yuman Fong; Michael I D'Angelica; Leslie H Blumgart; Ronald P Dematteo
Journal:  Ann Surg       Date:  2009-04       Impact factor: 12.969

View more
  2 in total

1.  Development of Nomograms for Predicting Prognosis of Pancreatic Cancer after Pancreatectomy: A Multicenter Study.

Authors:  So Jeong Yoon; Boram Park; Jaewoo Kwon; Chang-Sup Lim; Yong Chan Shin; Woohyun Jung; Sang Hyun Shin; Jin Seok Heo; In Woong Han
Journal:  Biomedicines       Date:  2022-06-07

2.  Impact of Intraoperative Blood Loss on the Survival of Patients With Stage II/III Colorectal Cancer: A Multicenter Retrospective Study.

Authors:  Hiroshi Tamagawa; Masakatsu Numata; Toru Aoyama; Keisuke Kazama; Yosuke Atsumi; Kenta Iguchi; Sho Sawazaki; Sumito Sato; Kazuki Kano; Takashi Ohshima; Takanobu Yamada; Teni Godai; Akio Higuchi; Hiroyuki Saeki; Norio Yukawa; Yasushi Rino
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.